Rocket Pharmaceuticals (RCKT) Equity Average (2016 - 2025)
Rocket Pharmaceuticals (RCKT) has disclosed Equity Average for 10 consecutive years, with $295.4 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 25.49% to $295.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $295.4 million through Dec 2025, down 25.49% year-over-year, with the annual reading at $370.2 million for FY2025, 22.53% down from the prior year.
- Equity Average hit $295.4 million in Q4 2025 for Rocket Pharmaceuticals, down from $333.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $516.8 million in Q4 2023 to a low of $295.4 million in Q4 2025.
- Historically, Equity Average has averaged $427.9 million across 5 years, with a median of $433.5 million in 2022.
- Biggest five-year swings in Equity Average: skyrocketed 91.81% in 2021 and later dropped 25.49% in 2025.
- Year by year, Equity Average stood at $470.2 million in 2021, then dropped by 8.87% to $428.5 million in 2022, then rose by 20.61% to $516.8 million in 2023, then decreased by 23.28% to $396.5 million in 2024, then decreased by 25.49% to $295.4 million in 2025.
- Business Quant data shows Equity Average for RCKT at $295.4 million in Q4 2025, $333.9 million in Q3 2025, and $383.2 million in Q2 2025.